Lonza Cuts Guidance on Lower Demand
Wall Street Journal
Lonza lowered its sales target and core Ebitda margin for 2023, as current market dynamics are hurting demand for early-stage services and nutraceutical capsules.
Wall Street Journal
Lonza lowered its sales target and core Ebitda margin for 2023, as current market dynamics are hurting demand for early-stage services and nutraceutical capsules.